ClinicalTrials.gov record
Terminated No phase listed Observational Results available

Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice

ClinicalTrials.gov ID: NCT01134315

Public ClinicalTrials.gov record NCT01134315. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 3:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules as Determined by Hypercalcemia in Pediatric Patients Ages 0 to 16 With Chronic Kidney Disease (CKD) Stage 5 Receiving Peritoneal Dialysis (PD) Within Current Clinical Practice

Study identification

NCT ID
NCT01134315
Recruitment status
Terminated
Study type
Observational
Phase
Not listed
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Enrollment
61 participants

Conditions and interventions

Interventions

  • Calcitriol Drug
  • Paricalcitol Drug

Drug

Eligibility (public fields only)

Age range
Up to 16 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2010
Primary completion
Apr 30, 2012
Completion
Apr 30, 2012
Last update posted
Aug 12, 2013

2010 – 2012

United States locations

U.S. sites
18
U.S. states
14
U.S. cities
18
Facility City State ZIP Site status
Site Reference ID/Investigator# 37082 Birmingham Alabama 35255
Site Reference ID/Investigator# 26762 Gainesville Florida 32610
Site Reference ID/Investigator# 28529 Orlando Florida 32801
Site Reference ID/Investigator# 26748 Atlanta Georgia 30322
Site Reference ID/Investigator# 37582 New Orleans Louisiana 70118
Site Reference ID/Investigator# 39973 Baltimore Maryland 21287
Site Reference ID/Investigator# 26769 Boston Massachusetts 02115
Site Reference ID/Investigator# 26768 Detroit Michigan 48201
Site Reference ID/Investigator# 26747 Kansas City Missouri 64108
Site Reference ID/Investigator# 26749 Akron Ohio 44308
Site Reference ID/Investigator# 26751 Cincinnati Ohio 45229
Site Reference ID/Investigator# 26765 Columbus Ohio 43205
Site Reference ID/Investigator# 28528 Oklahoma City Oklahoma 73104
Site Reference ID/Investigator# 26763 Portland Oregon 97227
Site Reference ID/Investigator# 28526 Charlottesville Virginia 22908
Site Reference ID/Investigator# 26758 Seattle Washington 98105
Site Reference ID/Investigator# 40382 Madison Wisconsin 53792
Site Reference ID/Investigator# 26759 Wauwatosa Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01134315, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 12, 2013 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01134315 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →